Macrogenics (MGNX) Tops Q3 EPS by 7c

Macrogenics (NASDAQ: MGNX) reported Q3 EPS of ($0.91), $0.07 better than the analyst estimate of ($0.98). Revenue for the quarter came in at $18.7 million versus the consensus estimate of $19.12 million.

“MacroGenics’ most advanced programs are positioned to initiate or complete registration-directed studies over the next year,” said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. “We look forward to presenting detailed data from the second interim OS analysis of SOPHIA, the Phase 3 study comparing margetuximab to trastuzumab in patients with metastatic HER2-positive breast cancer at the San Antonio Breast Cancer Symposium in December. We believe that our molecule, if approved, will address an important unmet need for patients. We continue our activities in preparation for a BLA submission before the end of the year.”

For earnings history and earnings-related data on Macrogenics (MGNX) click here.

You May Also Be Interested In

• JPMorgan is worried about further S&P 500 sell-off potential
• Peoples Bancorp (PEBO) Tops Q1 EPS by 4c
• Brown & Brown (BRO) Tops Q1 EPS by 7c